Shopping Cart (0)
My Account

 Shopping Cart
Conferences | Training Courses | Market Reports | Managed Events | Past Conferences | Update Me
SELECTBIO Conferences Biofluid Biopsies
Conferences  \  Biofluid Biopsies & High-Value Diagnostics 2015  \  Biofluid Biopsies  \  Agenda  \  Chris Karlovich
RegisterLogin

Chris Karlovich's Biography


Chris Karlovich, Associate Director, Molecular Diagnostics, Clovis Oncology, Inc.

Chris Karlovich is an Associate Director of Molecular Diagnostics at Clovis Oncology. He provides scientific and operational oversight over molecular diagnostics and companion diagnostic development for rociletinib (CO-1686), a mutant-selective inhibitor of EGFR in clinical trials for NSCLC. Prior to coming to Clovis, Dr. Karlovich spent nine years in the diagnostics industry in the areas of biomarker discovery and in vitro diagnostic (IVD) test development for companion diagnostics.

Chris Karlovich Image

Efficacy of Rociletinib in NSCLC Patients Selected with an EGFR Plasma Test

Monday, 16 November 2015 at 14:30

Add to Calendar ▼2015-11-16 14:30:002015-11-16 15:30:00Europe/LondonEfficacy of Rociletinib in NSCLC Patients Selected with an EGFR Plasma TestSELECTBIOenquiries@selectbiosciences.com

We are exploring blood-based molecular testing in clinical trials of rociletinib, a novel third-generation TKI that selectively inhibits the EGFR activating and T790M resistance mutations in NSCLC patients.  The utility of plasma-based EGFR mutational analysis for diagnosis, prediction of response to rociletinib, as a PD biomarker, and for ongoing monitoring of response will be described.

Add to Calendar ▼2015-11-16 00:00:002015-11-17 00:00:00Europe/LondonBiofluid BiopsiesSELECTBIOenquiries@selectbiosciences.com


Corporate Sponsors